Company news

BioCryst Pharmaceuticals, Inc. news in 2022

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

December 14, 2022

BioCryst to Present at JMP Securities Hematology & Oncology Summit

December 4, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

November 27, 2022

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

November 9, 2022

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

October 31, 2022

BioCryst to Report Third Quarter 2022 Financial Results on November 1

October 17, 2022

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

September 13, 2022

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

August 30, 2022

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

August 25, 2022

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

August 24, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

August 17, 2022

BioCryst Resumes Enrollment in BCX9930 Clinical Program

August 3, 2022

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

August 3, 2022

BioCryst to Report Second Quarter 2022 Financial Results on August 4

July 20, 2022

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

June 30, 2022

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

June 21, 2022

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

June 8, 2022

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

June 7, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

June 6, 2022

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

June 5, 2022

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

May 4, 2022

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

April 26, 2022

BioCryst to Report First Quarter 2022 Financial Results on May 5

April 20, 2022

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

April 7, 2022

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

February 23, 2022

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

February 22, 2022

BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases

February 21, 2022

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

February 8, 2022

BioCryst Appoints Machelle Sanders to Board of Directors

February 7, 2022

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

January 31, 2022

BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance

January 9, 2022

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

January 6, 2022

Calls in 2022

Decks in 2022